Pemigatinib for the treatment of metastatic or unresctable colorectal cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to see if the study drug, pemigatinib, is safe and effective for fighting a specific type of colorectal cancer.

What is the Condition Being Studied?

Colorectal Cancer

Who Can Participate in the Study?

Adults with colorectal cancer that:
-Is metastatic or unresectable; and
-Contains alterations in the genes FGFR1, FGFR2, or FGFR3

Additionally, eligible participants must have failed prior standard-of-care therapy or not be able to tolerate it.

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
-Take the study drug, pemigatinib, by mouth once per day
-Return to the clinic every 3 weeks so we can monitor your health
-Give blood and urine for testing
-Get CT or MRI scans every 9 weeks

You may be on the study drug for up to 2 years.

Study Details

Full Title
[ACCRU-GI-1701] A Phase II, Multicenter, Single-Arm Study of Pemigatinib in Patients with Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00105296
NCT: NCT04096417
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698